Huaren Pharmaceutical participates in the Beijing-Tianjin-Hebei "3+N" alliance for the selected procurement of certain Western medicines and traditional Chinese medicines through volume-based procurement

Huaren Pharmaceutical and its wholly-owned subsidiary participated in the "3+N" alliance for the procurement of Western medicine and traditional Chinese medicine in the Beijing-Tianjin-Hebei region, and were selected for multiple products. According to the announcement from the Tianjin Pharmaceutical Procurement Center, the expected sales revenue for the selected products in 2024 is RMB 13.0389 million, accounting for 0.96% of the company's operating revenue in 2024. Among them, the sales revenue of mixed sugar electrolyte injection, betamethasone sodium phosphate injection, and hydroxyethyl starch 130/0.4 sodium chloride injection accounts for 0.06%, 0.16%, and 0.74%, respectively